PMID- 18612893
OWN - NLM
STAT- MEDLINE
DCOM- 20080805
LR  - 20231024
IS  - 1532-4303 (Electronic)
IS  - 0277-0903 (Linking)
VI  - 45
IP  - 6
DP  - 2008 Aug
TI  - Asthma 2008: targeting immunoglobulin E to achieve disease control.
PG  - 429-36
LID - 10.1080/02770900802085485 [doi]
AB  - Traditionally, practice guidelines have recommended a step-wise approach to 
      treatment based on asthma severity and lung function. However, increasing 
      evidence suggests that asthma may not be adequately controlled in many patients 
      with moderate-to-severe disease despite aggressive therapy, and that regularly 
      evaluating the level of asthma control achieved in individual patients may be 
      more effective than disease severity in guiding treatment decisions. This is 
      reflected in updated asthma guidelines from the National Asthma Education and 
      Prevention Program, which advocate regular assessment of asthma control in terms 
      of the current impairment and future risk associated with the disease. 
      Guideline-recommended options for patients with persistent, moderate-to-severe 
      immunoglobulin E (IgE)-mediated asthma have recently been enhanced by the 
      inclusion of omalizumab. This change is based on growing evidence for the central 
      role of IgE in airway inflammation and asthma and the clinical effectiveness of 
      blocking IgE with omalizumab, a recombinant humanized monoclonal antibody. 
      Omalizumab significantly reduced asthma exacerbations and improved lung function 
      and symptoms in randomized controlled studies of patients inadequately controlled 
      on inhaled corticosteroids plus long-acting beta(2)-agonist therapy; these 
      benefits for reducing asthma impairment and risk were maintained during steroid 
      dose reductions. Omalizumab is well tolerated, although patients should be 
      monitored for possible rare anaphylactic reactions.
FAU - Prenner, Bruce M
AU  - Prenner BM
AD  - Allergy Associates Medical Group, Inc, San Diego, California 92120, USA. 
      prenner@aaamg.com
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Asthma
JT  - The Journal of asthma : official journal of the Association for the Care of 
      Asthma
JID - 8106454
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy/immunology
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Omalizumab
RF  - 59
EDAT- 2008/07/10 09:00
MHDA- 2008/08/06 09:00
CRDT- 2008/07/10 09:00
PHST- 2008/07/10 09:00 [pubmed]
PHST- 2008/08/06 09:00 [medline]
PHST- 2008/07/10 09:00 [entrez]
AID - 794834399 [pii]
AID - 10.1080/02770900802085485 [doi]
PST - ppublish
SO  - J Asthma. 2008 Aug;45(6):429-36. doi: 10.1080/02770900802085485.